Wellington’s Jean Hynes on the Art of Investing and Finding New Markets

August 18, 2026

AI Summary

5 min read

Jean Hynes, CEO of Wellington Management, did not set out to run a $1.3 trillion asset manager. When she joined the firm in 1991 as an administrative assistant, her mentor told her, “Don’t worry about the title.” She spent the next 25 years investing in healthcare, learning to dream about what a transformational drug could become while also learning the hard way that every line of a company’s P&L matters. In this conversation, Hynes walks through the psychology of disciplined investing, the structural shifts reshaping portfolio management, and what it means to lead a private partnership through an era of AI and geopolitical uncertainty.

The Art of Dreaming with Discipline

Hynes describes equity investing as “dreaming what is the potential of something that could be so transformational that people can’t imagine it.” Her early career taught her both sides of that coin. The positive lesson came from an investment in Immunex, the company behind Enbrel, the first drug to fundamentally change how inflammatory diseases like rheumatoid arthritis were treated. At the time, there was no market for such a drug — patients were treated with steroids. Hynes had to imagine both how fast the market would adopt it and what pricing could be, relying on conversations with rheumatologists to gauge real-world demand. “It was the beginning of really using physician specialists to dig into resea

Continue reading the full summary in the app — free to try.

Read Full Summary →

Free • No credit card required

Listen to Audio Summary Open in App

Never miss an episode of Exchanges

Get every new episode summarized in your inbox — free, ~5 minutes to read.

No spam. Unsubscribe anytime.

What you'll learn

1 (00:05) **Opening: Dreaming as the Art of Equity Investing** - Host Alison Mass introduces Jean Hynes, CEO of Wellington Management ($1.3 trillion AUM). Hynes frames the core of equity investing as "dreaming what is the potential of something so transformational that people can't imagine it."
2 (03:35) **The Path to CEO: From "Absolutely Not" to "Maybe I Do"** - Hynes explains how her ambition shifted after working with an executive coach in 2014.
3 (05:18) **Wellington’s Decade-by-Decade Expansion** - Hynes walks through the firm's evolution from a primarily value-equity shop in 1991 to a multi-asset global manager.
4 (08:55) **Attracted to Healthcare by Mentorship, Not Passion** - Hynes reveals she was initially "not necessarily attracted" to healthcare but was given the opportunity to work with 20-year mentor Ed Owens.
5 (10:18) **Two Pivotal Early Investment Lessons** - Hynes shares a mistake and a triumph that shaped her approach.
6 (13:58) **The Biopharma Patent Cliff and Sector Outlook** - Hynes addresses the perpetual challenge of patent expirations and recent healthcare underperformance.
7 (16:26) **Medical Advances to Watch in the Next 5-10 Years** - Hynes identifies two areas of greatest remaining medical need and innovation.

+ Full timestamped outline available in the app

Show Notes

Jean Hynes, CEO of Wellington Management, has more than 35 years of experience at the firm. But she spends most of her time looking ahead, trying to envision what the world might look like in a decade and building portfolios around nascent opportunities. In an interview with Goldman Sachs’ Alison Mass on the Great Investors podcast, Hynes discusses innovation in the biopharma sector, how Wellington is using AI, and her path to the C-Suite.

The opinions and views expressed herein are as of the date of publication, subject to change without notice, and may not necessarily reflect the institutional views of Goldman Sachs or its affiliates. The material provided is intended for informational purposes only, and does not constitute investment, legal, or tax advice, a recommendation from any Goldman Sachs entity to take any particular action or be used as a basis for any other investment decision, or an offer or solicitation to purchase or sell any securities or financial products. Any forward-looking statements, case studies, computations or examples set forth herein are for illustrative purposes only. Past performance is not indicative of future results. Neither Goldman Sachs nor any of its affiliates make any representations or warranties, express or implied, as to the accuracy or completeness of the statements or information contained herein and disclaim any liability whatsoever for reliance on such information for any purpose. Each name of a third-party organization mentioned is the property of the company to which it relates, is used here strictly for informational and identification purposes only and is not used to imply any sponsorship, affiliation, endorsement, ownership or license rights between any such company and Goldman Sachs. This material should not be copied, distributed, published, or reproduced in whole or in part or disclosed by any recipient to any other person without the express written consent of Goldman Sachs.

A transcript is provided for convenience and may differ from the original video or audio content. Goldman Sachs is not responsible for any errors in the transcript.

Date of Recording: July 20, 2026

Learn more about your ad choices. Visit megaphone.fm/adchoices